Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602536 · ClinicalTrials.gov registry record · NA
Twitter-enabled Mobile Messaging for Smoking Relapse Prevention
A NA study, sponsored by University of California, Irvine.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT01602536: Completed NA study, sponsored by University of California, Irvine.
NCT01602536 is a NA study that has completed, run by University of California, Irvine. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01602536, a NA study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
We conducted a two-arm (test vs. control, N=160) randomized controlled trial of small, private, online support groups for quitting smoking with 20 people per group who were seeking to quit smoking. A novel feature was a bot (auto-messenger) that posted a daily cessation-related discussion topic in each group, timed to the group's quit date.
Primary Outcome
self-reported 7-day point prevalence abstinence from smoking that was sustained at 60 days after the quit date, based on survey
Interventions
- BEHAVIORAL smoking cessation aides
- BEHAVIORAL Twitter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-06 |
| Phase | NA |
What the finished NCT01602536 record still lists
NCT01602536 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which smoking cessation aides is the first listed.
NCT01602536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01602536 about?
NCT01602536 is a clinical study titled "Twitter-enabled Mobile Messaging for Smoking Relapse Prevention". We conducted a two-arm (test vs. control, N=160) randomized controlled trial of small, private, online support groups for quitting smoking with 20 people per group who were seeking to quit smoking. A novel feature was a bot (auto-messenger) that posted a daily cessation-related discussion topic in e...
What is the current status of trial NCT01602536?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2012-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01602536?
The interventions under investigation include: smoking cessation aides (BEHAVIORAL), Twitter (BEHAVIORAL).
Who is sponsoring clinical trial NCT01602536?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01602536's enrollment target sits among peer trials
160 628th of 2000 higher than 1,347 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia